Simon is new FDA anti-inflammatory division director
This article was originally published in Pharmaceutical Approvals Monthly
Lee Simon, MD, will start Nov. 19 as director of Division of Anti-Inflammatory, Analgesic and Ophthalmic Drug Products, replacing Acting Director Jonca Bull, MD. Simon, an associate professor of medicine at Harvard Medical School, was a principal investigator and lead author of Celecoxib Long-term Arthritis Safety Study. He has served as a consultant to Lilly, Forest, Aventis and Pharmacia/Searle
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."